Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Cisatracurium besylate
Cat. No.:
OB0225LY-0307
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Cisatracurium besylate is a neuromuscular blocking agent used primarily for muscle relaxation during anesthesia.
Synonym:
51W89; 96946-42-8; Nimbex; Cisatracurium (besylate); (1R)-cis,1'R)-cis)-Atracurium besylate; (1R,1'R,2R,2'R)-2,2'-((Pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium) benzenesulfonate; (1R,2R)-2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate, pentamethylene ester
CAS No.:
96946-42-8
Compound CID:
62886
Formula:
C53H72N2O12·2C6H5O3S
Formula Weight:
1243.48
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Cisatracurium besylate can be used for anesthesiology research.
Library Information
Targets:
G protein-coupled receptors (GPCRs)
Receptors:
Adrenergic receptor; nAChR
Pathways:
Neuronal signaling; Autophagy; GPCR/G protein
Plate Number:
AOCL-4
Plate Location:
h9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
229 mg/mL; 184.2 mM
Water Max Solubility:
43 mg/mL; 34.6 mM
Ethanol Max Solubility:
229 mg/mL; 184.2 mM
